We compared DNA replication, protein biosynthesis, and mitogen-activated protein kinase (MAPK) activity in Rat 1 fibroblasts stably expressing either the ␣ 1B -adrenergic receptor (AR) or ␣ 1D -AR subtypes. Activation of both the ␣ 1B -AR and ␣ 1D -AR inhibited DNA synthesis (as assessed by [
Three genes encoding unique ␣ 1 -AR subtypes, ␣ 1A -, ␣ 1B -, or ␣ 1D -AR, have been cloned and pharmacologically characterized (Cotecchia et al., 1988; Schwinn et al., 1990; Lomasney et al., 1991; Perez et al., 1991; Hieble et al., 1995) . All three ␣ 1 -AR subtypes exhibit similar affinity for endogenous catecholamines (Schwinn et al., 1990; Lomasney et al., 1991; Perez et al., 1991) ; however, the cellular functions of these receptors have not been adequately defined. Our previous work showed that although all receptor subtypes are expressed in peripheral arteries, the ␣ 1A -AR or ␣ 1D -AR couple agonist binding to smooth muscle contraction in a given vessel (Guarino et al., 1996; Hrometz et al., 1999; Piascik and Perez, 2001) . In addition to the acute regulation of blood pressure, catecholamines induce vascular smooth muscle cell growth (Johnson et al., 1983; deBlois et al., 1996; Fingerle et al., 1991; van Kleef et al., 1992; Chen et al., 1995) . These observations suggest that expressed ␣ 1 -AR subtypes may differentially activate signaling pathways and physiological responses.
Mitogen-activated protein kinases (MAPKs) are important mediators of cell growth, proliferation, differentiation, and survival. There are three major MAPK subtypes: the extracellular signal-regulated kinases (ERK1/2), c-Jun NH 2 -terminal kinases (JNKs), and p38 kinases (Widmann et al., 1999) . Activated MAPKs translocate to the nucleus and phosphorylate multiple transcription factors to increase transcriptional activity (Widmann et al., 1999) . ERK1/2 and p38 kinase also phosphorylate cytoplasmic substrates, including those involved in protein biosynthesis (Widmann et al., 1999) . Recent studies suggest that ␣ 1 -AR subtypes differentially activate MAPK family members and that the profile of MAPK activation uniquely impacts on cellular phenotype (Alexandrov et al., 1999; Zhong and Minneman, 1999; Keffel et al., 2000) . For example, in PC12 cells, inducible expression and activation of the ␣ 1A -AR, but not the ␣ 1B -AR or the ␣ 1D -AR subtypes, leads to activation of ERK1/2, JNK, and p38 kinase and promotes neurite outgrowth (Zhong and Minneman, 1999) .
Discernment of the role of ␣ 1 -AR subtypes in long-term growth responses in tissues that express multiple receptor subtypes is hindered by the lack of ␣ 1 -AR subtype-selective agonists. An added complexity in studying the specific role of ␣ 1 -AR subtypes in long-term responses is the observation that endogenous ␣ 1 -ARs are differentially regulated by chronic agonist exposure in myocardial and vascular smooth muscle cells (Chen et al., 1995; Rokosh et al., 1996) . As an alternative approach to study the regulatory roles of ␣ 1 -ARs, several laboratories have compared signaling properties of ␣ 1 -AR receptor subtypes in heterologous expression systems. These studies have demonstrated intrinsic differences between the ␣ 1 -AR subtypes within a cell line and cellular responses for a given ␣ 1 -AR expressed in different host cell lines.
Endogenously expressed ␣ 1A -ARs mediate hypertrophic growth of myocardial cells (Varma and Deng, 2000) . Furthermore, accumulating evidence suggests that ␣ 1A -ARs, and to a lesser extent ␣ 1D -ARs, regulate arterial blood pressure (Piascik and Perez, 2001 ). The functional roles of the ␣ 1B -AR and ␣ 1D -AR in cardiovascular tissues are not well understood. We previously reported divergent regulation of subcellular localization and acute signaling events by ␣ 1B -AR and ␣ 1D -AR expressed in Rat 1 fibroblasts (McCune et al., 2000) . The ␣ 1B -AR exhibits properties of a typical G protein-coupled receptor because it is expressed primarily on the cell surface and demonstrates agonist-dependent internalization and ERK1/2 activation (McCune et al., 2000) . In contrast, the ␣ 1D -AR localizes primarily in internalized subcellular compartments and shows evidence of enhanced ERK1/2 and phospholipase activity in the absence of agonist (McCune et al., 2000) . In this report, we examined JNK and p38 kinase activation, cellular proliferation, and protein biosynthesis mediated by these receptor subtypes. Both receptors inhibited DNA synthesis and increased protein biosynthesis and ERK1/2 activity. Interestingly, ERK1/2 and protein biosynthesis were agonist-dependent for ␣ 1B -AR and agonist-independent for the ␣ 1D -AR, suggesting constitutive ERK1/2 activity was coupled to protein biosynthesis. We also demonstrated divergent regulation of JNK and p38 kinase by these receptor subtypes. For example, the ␣ 1B -AR activated p38 kinase but not JNK, whereas the ␣ 1D -AR was coupled to JNK but not p38 kinase activation. Finally, we show that the ␣ 1B -AR, but not ␣ 1D -AR, mediated growth effects through a p38 kinase-dependent pathway. Therefore, although the ␣ 1B -AR and ␣ 1D -AR mediate similar effects on growth responses, they exhibit different requirements for agonist activation and MAPK isoforms.
Materials and Methods
Cell Culture. Rat 1 fibroblasts stably transfected with either the cloned human ␣ 1B -or ␣ 1D -AR (GlaxoSmithKline, Uxbridge, Middlesex, UK) were cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma Chemical, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA), 1% penicillinstreptomycin mixture (Invitrogen), and Geneticin (250 g/ml; Invitrogen) at 37°C in 5% CO 2 . Twenty-four hours after plating, cells were washed and then serum-deprived for 48 h before the addition of drugs.
[ 3 H]Thymidine Incorporation. Rat 1 fibroblasts plated on 24-well dishes at 1 ϫ 10 4 cells/well were treated with the indicated drugs for 24 h with 1 Ci [ 3 H]thymidine (PerkinElmer Life Sciences, Boston, MA) included during the last 6 h of incubation. Kinase inhibitors were added 20 min before phenylephrine (PE). Cells were rinsed with phosphate-buffered saline (PBS), fixed for 10 min with ice-cold methanol, washed 3 ϫ 5 min with ice-cold 10% trichloroacetic acid, and dissolved in 1 N sodium hydroxide. [
3 H]Thymidine incorporation was quantified using liquid scintillation counting and used as an index of DNA synthesis.
[ 35 S]Methionine Incorporation. Incorporation of [ 35 S]methionine in Rat 1 fibroblasts was performed as described by Xin et al. (1997) with modifications (Xin et al., 1997) . Serum-deprived Rat 1 fibroblasts plated on 24-well dishes at 1 ϫ 10 4 cells/well were washed twice with methionine-free DMEM and incubated for 30 min. Cells were then treated with the indicated drugs in low-methionine (2 mg/l) DMEM for 24 h. Kinase inhibitors were added 20 min before PE. [
35 S]Methionine (1 Ci; PerkinElmer Life Sciences) was added during the last 6 h of incubation. Sample processing was essentially the same as for thymidine incorporation assay. [
35 S]Methionine incorporation was quantified using liquid scintillation counting and served as an index of protein synthesis.
Preparation of GST-c-Jun(1-135). Recombinant c-Jun [c-Jun(1-135)] was produced in Escherichia coli as a glutathione S-transferase fusion protein expressed from plasmid pGEX-c-Jun (Prasad et al., 1995) . GST-c-Jun(1-135) fusion protein was purified by conjugation to glutathione-Sepharose beads (Amersham Pharmacia Biotech AB, Uppsala, Sweden) and eluted with 20 mM glutathione in 100 mM Tris, pH 8. The eluate was dialyzed for 2 h at 4°C to remove glutathione. ERK1/2 Activity Assay. ERK1/2 activity was detected by the in-gel method as described previously (McCune et al., 2000) . Cells were treated with the indicated drugs, washed with ice-cold PBS, and scraped into 1 ml of 250 mM ice-cold buffered sucrose. Cell pellets were resuspended in cold lysis buffer [20 mM Tris-HCl, pH 7.4, 250 mM NaCl, 2.5 mM EDTA, 3 mM EGTA, 20 mM ␤-glycerophosphate, 0.5% (v/v) Nonidet P-40, 100 M Na 3 VO 4 , and protease inhibitors (Calbiochem, La Jolla, CA)] for 30 min, centrifuged (15 min; 15,000g; 4°C), and the supernatant collected. Protein was resolved on 10% SDS-polyacrylamide gels containing 0.5 mg/ml myelin basic protein (MBP). After electrophoresis, the gels were washed with 20% 2-propanol in 50 mM HEPES, pH 7.6, and then with 5 mM ␤-mercaptoethanol in HEPES buffer. Proteins were denatured in 6 M urea and gradually renatured in HEPES buffer containing 0.05% (v/v) Tween 20 and 5 mM ␤-mercaptoethanol (renaturation buffer) at 4°C. After overnight incubation in renaturation buffer at 4°C, gels were preincubated in 25 ml of cold kinase buffer (20 mM HEPES, 20 mM MgCl 2 , 2 mM dithiothreitol, 5 mM ␤-glycerophosphate, 100 M Na 3 VO 4 , pH 7.6) for 30 min. Phosphorylation of MBP was performed in situ by soaking the gel in 25 ml of kinase buffer containing 20 M ATP and 150 to 160 Ci of [␥- 32 P]ATP (New England Biolabs, Beverly, MA) for 90 to 120 min at 30°C. After extensive washing with 5% trichloroacetic acid/1% sodium pyrophosphate the gels were dried and exposed to film. 32 P incorporation into MBP was determined by densitometric analysis.
JNK Activity Assay. Activities of the 46-and 55-kDa isoforms of JNK were determined by in-gel activity assays essentially as described for ERK1/2, except 0.1 mg/ml GST-c-Jun(1-135) was used as substrate.
p38 Kinase Immunoblotting. Cells were maintained in serumfree media or treated with PE (100 M) or anisomyosin (50 ng/ml) for 15 min. Cells were washed twice with ice-cold PBS and lysed with 150 l of SDS-sample buffer. The lysates were sonicated (5 ϫ 2 s), boiled for 5 min, and cooled on ice. Equal volumes of lysate were resolved on 10% SDS-polyacrylamide gels and transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA). Phosphorylated and total p38 kinase was detected by protein immunoblotting with a 1:1000 dilution of rabbit polyclonal phosphospecific (Thr180/ Tyr192) or total p38 kinase antibodies (New England Biolabs). Primary antibody was detected with 1:2000 horseradish peroxidaseconjugated donkey anti-rabbit secondary antibody (Amersham Pharmacia Biotech AB). Bands were visualized by chemiluminescence (ECLϩ; Amersham Pharmacia Biotech AB) and quantitated by phosphorimaging (Molecular Dynamics, Sunnyvale, CA).
Data Analysis. Differences among treatment groups were detected by one-or two-way analysis of variance with repeated measures followed by Student-Newman-Keuls multiple comparison tests. In the absence of a significant treatment by treatment group interaction, the statistical significance of the main or overall effect of a particular treatment is reported. Differences between the cell lines were detected by unpaired, two-tailed Student's t test. All calculations were performed using the Statistica program (release 5.1; StatSoft, Tulsa, OK). A p Ͻ 0.05 was considered significant. Nonlinear regression analyses of concentration-response curves were performed using GraphPad Prism (version 2.01; GraphPad Software, San Diego, CA).
Results
Agonist Activation of ␣ 1B -and ␣ 1D -AR Inhibits DNA Synthesis. The studies presented here extend our previous report demonstrating differences in the regulatory properties of the ␣ 1B -and ␣ 1D -AR (McCune et al., 2000) . To determine the role of ␣ 1B -AR and ␣ 1D -ARs in cellular proliferation, we examined PE-mediated (Table 1) . PE (1 M) reduced DNA synthesis to 44 Ϯ 2% of that observed in unstimulated ␣ 1B -AR cells and 17 Ϯ 4% for the ␣ 1D -AR. The effect of PE on DNA synthesis was blocked by 1 M prazosin (nonselective ␣ 1 -AR antagonist) in both cell lines and not affected by either 1 M yohimbine (␣ 2 -AR antagonist) or 1 M propranolol (␤-AR antagonist), suggesting that agonist-induced inhibition of DNA synthesis was mediated through the expressed ␣ 1 -AR.
Coupling of ␣ 1B -and ␣ 1D -ARs to Protein Biosynthesis. Because ␣ 1 -ARs are known to regulate both proliferative and hypertrophic growth responses, we also examined 35 S]methionine incorporation in a concentration-dependent manner in ␣ 1B -and ␣ 1D -AR-expressing fibroblasts (Fig. 2) , with a greater maximal effect of PE in the ␣ 1B cell line (238 Ϯ 16 versus 162 Ϯ 29%; p Ͻ 0.05). Differences in agonist and basal [
35 S]methionine incorporation between the two cell lines were not due to differences in cell number (data not shown). The Ϫlog EC 50 values for two receptors were similar for the two cell lines (␣ 1B -AR, 7.2 Ϯ 0.3; ␣ 1D -AR, 6.9 Ϯ 0.5; N.S.).
Coupling of ␣ 1B -and ␣ 1D -ARs to ERK1/2. We compared the ability of these receptor subtypes to regulate ERK1/2 activation (Fig. 3) . In ␣ 1B -AR-expressing cells, PE (100 M; 5 min) significantly increased ERK1/2 activity over basal levels (*p Ͻ 0.05). In contrast, we did not detect PE-or seruminduced increases in ERK1/2 activity for the ␣ 1D -AR. Basal ERK1/2 activity was 2-fold greater in the ␣ 1D -AR-expressing cells (␣ 1B , 1.7 Ϯ 0.8 IOD; ␣ 1D , 3.5 Ϯ 0.9 IOD) and similar in magnitude to the ␣ 1B cell line treated with PE (␣ 1B , 4.7 Ϯ 1.8 IOD). We previously showed that 1 M prazosin inhibited basal ERK1/2 activity by ϳ50% in ␣ 1D -AR-expressing cells (McCune et al., 2000) . High basal ERK1/2 activity may have precluded our ability to observe further increases in ERK1/2 activity induced by 10% fetal bovine serum or PE.
Coupling of ␣ 1B -and ␣ 1D -ARs to JNK. We examined the ability of PE and anisomyosin (positive control) to activate JNK in ␣ 1B -AR-and ␣ 1D -AR-expressing fibroblasts (Fig. 4) . Although anisomyosin (50 ng/ml) stimulated JNK activity to Downloaded from a similar extent in both cell lines, PE (100 M; 20 min) increased JNK activity only in ␣ 1D -AR fibroblasts (*p Ͻ 0.01). Basal JNK activity was similar in both ␣ 1B -AR-and ␣ 1D -AR-expressing fibroblasts (average basal activity of ␣ 1B relative to ␣ 1D was 75 Ϯ 30%; n ϭ 4; N.S.). Coupling of ␣ 1B -and ␣ 1D -ARs to p38 Kinase. We compared the ability of PE to activate p38 kinase in both cell lines by immunoblotting for phospho-and total p38 kinase in unstimulated, PE-, or anisomyosin-treated cell lines (Fig. 5) . PE (100 M; 15 min) induced p38 kinase activity in ␣ 1B -AR, but not in ␣ 1D -AR-expressing fibroblasts (*p Ͻ 0.05).
PD98059 Blocks PE-Induced ERK1/2 Activation in ␣ 1B -AR Cells and Decreases Basal ERK1/2 Activity in ␣ 1D -AR Cells. Activation of MAPK family members requires phosphorylation on both threonine and tyrosine by dual specificity kinases (Widmann et al., 1999) . To assess the role of ERK1/2 and p38 kinase in ␣ 1 -AR-mediated DNA and protein biosynthesis we used selective cell-permeable inhibitors of these MAPK isoforms. Rat 1 fibroblasts were pretreated for 20 min with DMSO (0.1% v/v; control), 10 M PD98059, a selective inhibitor of ERK1/2 activation (Dudley et al., 1995) , or the p38 kinase inhibitor SB203580. After 5 min of PE or 10% FBS (control for ERK1/2 activation) treatment, cell ly- 3 . Phenylephrine activates ERK1/2 in ␣ 1B -but not ␣ 1D -AR-expressing Rat 1 fibroblasts. Rat 1 fibroblasts were maintained in serum-free DMEM (control), or treated with DMEM containing PE (100 M), or 10% fetal bovine serum for 5 min. Cell lysates were prepared and equal amounts of protein were separated by SDS-PAGE containing 0.5 mg/ml myelin basic protein (substrate for ERK1/2) and ERK1/2 activity determined by in-gel assays. Data shown are the means Ϯ S.E.M. from six separate experiments performed in duplicate and are normalized to percentage of control for each cell line ( ‫ء‬ , PE-induced ERK1/2 in ␣ 1B -ARversus ␣ 1D -AR-expressing cells; p Ͻ 0.05). Basal levels of ERK activity in the ␣ 1D cell line were nearly 2-fold greater than that observed for the ␣ 1B cell line (␣ 1B , 1.7 Ϯ 0.8 IOD; ␣ 1D , 3.5 Ϯ 0.9 IOD). Fig. 4 . Phenylephrine activates c-Jun NH 2 -terminal kinase in ␣ 1D -but not ␣ 1B -expressing Rat 1 fibroblasts. Cells were untreated (control), or treated with PE (100 M) or anisomycin (50 ng/ml) for 20 min. Lysates were collected and equal amounts of protein were separated by SDS-PAGE containing 0.1 mg/ml GST-cJun fusion protein. The gels were dried and subjected to autoradiography followed by densitometric analysis. The average basal activity of ␣ 1B relative to ␣ 1D was 75 Ϯ 30% (N.S.). Data shown are the means Ϯ S.E.M. from four separate experiments performed in duplicate and are normalized to percentage of control for each cell line ( ‫ء‬ , PE-induced JNK activity in ␣ 1B -AR-versus ␣ 1D -AR-expressing fibroblasts; p Ͻ 0.01). A representative autoradiograph is shown. Fig. 5 . Phenylephrine activates p38 kinase in ␣ 1B -but not ␣ 1D -expressing Rat 1 fibroblasts. Cells were untreated (C), or incubated with PE (100 M) or anisomycin (50 ng/ml; An) for 15 min. Equal amounts of protein were separated by 10% SDS-PAGE and subjected to immunoblotting as described under Materials and Methods. Columns represent means Ϯ S.E.M. of four to five separate experiments ( ‫ء‬ , PE-induced p38 activity in ␣ 1B -AR-versus ␣ 1D -AR-expressing fibroblasts; p Ͻ 0.05.) Representative autoradiographs of phospho-and total p38 kinase are shown. sates were prepared and ERK1/2 activity was determined using in-gel kinase assays. As shown in Fig. 6 , PE-induced ERK1/2 activation in ␣ 1B -AR-expressing cells was blocked by PD98059. Unlike a previous report demonstrating inhibition of ERK1/2 activity by p38 kinase in Rat 1 fibroblasts (Alexandrov et al., 1999), we did not detect differences in either basal or agonist-induced ERK1/2 activity in the presence of SB203580. Relative to the ␣ 1B -AR, ␣ 1D -AR-expressing cells displayed elevated ERK1/2 activity in the absence of agonist that was inhibited by PD98059.
SB203580 Blocks PE-Induced p38 Kinase Activation in ␣ 1B -AR Cells. To demonstrate the inhibitory effect of p38 kinase inhibitor SB203850 on ␣ 1 -AR-mediated responses, cells were preincubated for 20 min with DMSO (0.1% v/v) or 10 M SB203580 before the addition of PE (100 M; 20 min). Cells were harvested and equal volumes of cell lysates were separated by SDS-PAGE and immunoblotted for phospho-or total p38 kinase (Fig. 7) . In ␣ 1B -AR cells, PE-mediated increases in phospho-38 kinase were blocked by SB203580. In contrast, PE did not activate p38 kinase in the ␣ 1D -AR cell line.
Role of ERK1/2 in ␣ 1 -AR-Mediated DNA and Protein Biosynthesis. Both ␣ 1B -AR and ␣ 1D -ARs inhibited DNA synthesis in Rat 1 fibroblasts (Fig. 1) . Cell cycle arrest in HepG2 cells overexpressing ␣ 1B -AR occurs through an ERK1/ 2-dependent pathway (Auer et al., 1998) . To investigate the role of ERK1/2 in ␣ 1 -AR-mediated alterations in DNA synthesis, we examined [ 3 H]thymidine incorporation in the absence and presence of 10 M PD98059. Although PD98059 blocked ERK1/2 activation in both cell lines (Fig. 6 ), PD98059 did not reverse PE-mediated decreases in [
3 H]thymidine incorporation in either cell line (Fig. 8, A and C) , indicating that these ␣ 1 -ARs regulate DNA synthesis through an ERK1/ 2-independent pathway.
In contrast to its inhibitory effects on DNA biosynthesis, PE significantly increased protein synthesis in ␣ 1B -AR-expressing fibroblasts ( Fig. 8B ; ***p Ͻ 0.001). Agonist-mediated activation of protein biosynthesis was inhibited ϳ50% by 10 M PD98059 ( Fig. 8B; ϩϩ p Ͻ 0.01 versus PE alone). PE increased [ 35 S]methionine incorporation in ␣ 1D -AR fibroblasts (Fig. 8D) , but the observed increase in this series of experiments did not attain statistical significance (Fig. 2) . Interestingly, basal [ Role of p38 Kinase in ␣ 1 -AR-Induced DNA and Protein Biosynthesis. In contrast to PD98059, 10 M SB203580 reversed ␣ 1B -AR-mediated inhibition of DNA synthesis by ϳ50% ( Fig. 9A; ϩϩ p Ͻ 0.01 compared with PE alone), suggesting that inhibition of DNA replication occurs, in part, through a p38 kinase-dependent pathway. Agonistinduced protein biosynthesis in ␣ 1B -AR cells was also inhibited ϳ50% by SB203580 ( Fig. 9B; ϩϩ p Ͻ 0.01 versus PE alone). In contrast, SB203580 had no effect on either [
3 H]thymidine incorporation (Fig. 9C) or [ 35 S]methionine incorporation (Fig. 9D) in ␣ 1D -AR-expressing fibroblasts. The effect of SB203580 on unstimulated DNA synthesis was not significantly different between the two cell lines. Combined PD and SB treatment in ␣ 1B -AR cells completely blocked the effect of PE on protein synthesis [control, 7.8 Ϯ 0.9 cpm (ϫ 10 3 ); PE, 20.5 Ϯ 2.6 cpm (ϫ 10 3 ), p Ͻ 0.001; PD ϩ SB, 6.7 Ϯ 0.6 cpm (ϫ 10 3 ), N.S.; PE ϩ PD/SB, 8.0 Ϯ 1.0 cpm (ϫ 10 3 ), N.S.], indicating that the ␣ 1B -AR uses both ERK1/2 and p38 kinase cascades to promote protein biosynthesis.
Discussion
␣ 1 -ARs are important mediators of arterial blood pressure, vascular smooth muscle contraction, and growth. Multiple ␣ 1 -AR subtypes are expressed in peripheral arteries; however, whether the same ␣ 1 -AR subtype regulates both contractile and growth responses in vivo and whether this growth represents hypertrophy, hyperplasia, or both have not been adequately defined. Definitive assessment of ␣ 1 -AR- jpet.aspetjournals.org mediated growth responses in vivo is hindered by the lack of ␣ 1 -AR subtype-selective compounds and differential regulation of receptor expression by prolonged agonist exposure (Chen et al., 1995; Rokosh et al., 1996) . However, several laboratories have shown differential coupling of ␣ 1 -AR subtypes to MAPK activation (Zhong and Minneman, 1999; Keffel et al., 2000; McCune et al., 2000) and [
3 H]thymidine incorporation (Keffel et al., 2000) in heterologous cell expression systems, suggesting that ␣ 1 -AR subtypes might differentially activate cellular growth responses.
To further examine the regulatory functions of the ␣ 1B -AR and ␣ 1D -AR, we compared cell proliferation, protein biosynthesis, and the MAPK isoforms mediating these growth responses in Rat 1 fibroblasts stably expressing these receptor subtypes. Despite similar levels of receptor expression (between 5.5 and 10 pmol/mg of protein; McCune et al., 2000) and the overall similarity of effect on cell proliferation and protein biosynthesis, our results reveal differential requirements for agonist and MAPK activation between these receptor subtypes. Agonist treatment of ␣ 1B -AR-expressing fibroblasts induces protein biosynthesis (Fig. 2) , ERK1/2 activity ( Fig. 3 ; McCune et al., 2000) , and p38 kinase activity (Fig. 5) , but has no effect on JNK activity (Fig. 4) and inhibits DNA synthesis (Fig. 1) . In contrast, protein biosynthesis and ERK1/2 activity are elevated in the absence of agonist in ␣ 1D -AR cells. Although ERK1/2 activity and protein biosynthesis are agonist-independent for the ␣ 1D -AR, JNK activity and inhibition of [ 3 H]thymidine incorporation are agonistdependent, suggesting that the ␣ 1D -AR is not constitutively linked to these responses in Rat 1 fibroblasts.
The overall pattern of MAPK activation and cellular growth responses observed in Rat 1 fibroblasts is distinct from ␣ 1 -AR subtypes expressed in either CHO or PC12 cells. Similar to results obtained in PC12 cells, activation of ␣ 1B -AR in Rat 1 fibroblasts cells increases ERK1/2 and p38 kinase activity, but does not activate JNK. However, although ␣ 1B -AR mediates increased protein biosynthesis and inhibition of DNA replication in Rat 1 fibroblasts, this receptor subtype does not affect DNA replication when expressed in CHO cells (Keffel et al., 2000) . Expression and activation of the ␣ 1D -AR stimulate DNA replication, p38 kinase, and JNK in CHO cells (Keffel et al., 2000) but activate only ERK1/2 in PC12 cells (Zhong and Minneman, 1999 ). In contrast, agonist activation of the ␣ 1D -AR inhibits DNA replication (Fig. 1) , activates JNK (Fig. 4) , and has no effect on p38 kinase activity (Fig. 5) in Rat 1 fibroblasts. Furthermore, studies in PC12 and CHO cells failed to report constitutive regulation of MAPK isoforms or growth responses for ␣ 1D -AR, although this receptor constitutively activates calcium transients in Rat 1 fibroblasts (Garcia-Sainz and TorresPadilla, 1999) . Several reports have shown that the ␣ 1D -AR is weakly coupled to intracellular signals (Theroux et al., 1996 ; at ASPET Journals on July 10, 2017 jpet.aspetjournals.org Downloaded from Ruan et al., 1998; Taguchi et al., 1998 ). An apparent lack of agonist-mediated, growth-related responses is consistent with constitutive or agonist-independent signaling by the ␣ 1D -AR. The overall conclusion from heterologous expression studies is that growth-related responses are dependent on ␣ 1 -AR subtype and host cell. Whether ␣ 1 -AR subtypes differentially regulate MAPK activity and growth of various peripheral arteries is the focus of our ongoing investigations.
Our results indicate that ERK1/2 activation is associated with increased protein biosynthesis rather than proliferative growth of Rat 1 fibroblasts. For example, the ERK1/2 pathway inhibitor PD98059 blocks ERK1/2 activity in ␣ 1B -ARand ␣ 1D -AR-expressing cells (Fig. 6 ), but does not reverse agonist-mediated inhibition of [ 3 H]thymidine incorporation in either cell line (Fig. 8, A and C) , suggesting that ERK1/2 activation is not required for ␣ 1 -AR-mediated inhibition of DNA synthesis. In contrast to its effects on PE-mediated DNA replication, PD98059 attenuates PE-mediated increases in [
35 S]methionine incorporation in ␣ 1B -AR-expressing cells (Fig. 8B) , suggesting this receptor couples agonist binding to protein biosynthesis through ERK1/2. Basal [ 35 S]methionine incorporation is elevated in ␣ 1D -AR-relative to ␣ 1B -AR-expressing fibroblasts (Fig. 8, compare B and D) . The ERK1/2 pathway inhibitor PD98059 blocks basal ERK1/2 activity (Fig. 6) and [ 35 S]methionine incorporation (Fig. 8D) , suggesting that constitutive ERK1/2 activity is coupled to increases in protein biosynthesis in ␣ 1D -AR-expressing cells. The physiological significance of agonist-dependent increases in ERK1/2 and protein biosynthesis by the ␣ 1B -AR and constitutive activity of these responses by the ␣ 1D -AR are not known. We did not observe increases in cell size (hypertrophy) in unstimulated ␣ 1D -AR cells or in agonist-treated ␣ 1B -ARs (data not shown). It is possible that constitutive activation of ERK1/2 for ␣ 1D -ARs or agonistmediated increases in ERK1/2 via ␣ 1B -ARs induces a differentiated or synthetic phenotype characterized by constitutive synthesis of extracellular matrix proteins in Rat 1 fibroblasts.
In contrast to the requirement for ERK1/2 activation in [ 35 S]methionine incorporation, inhibition of DNA synthesis occurs through an ERK1/2-independent pathway for both ␣ 1 -AR subtypes (Fig. 10 ). Similar to a previous study examining DNA synthesis in CHO cells expressing the ␣ 1A -AR (Keffel et al., 2000) , the p38 kinase inhibitor SB203850 reverses PE-mediated inhibition of [ 3 H]thymidine incorporation in the ␣ 1B -AR cell line (Fig. 9A) . The lack of effect of SB203580 on PE-mediated inhibition of [ 3 H]thymidine incorporation and elevated basal [
35 S]methionine incorporation in the ␣ 1D -AR cell line is consistent with the inability of this receptor subtype to induce p38 kinase activation (Fig. 5) . Therefore, inhibition of [ 3 H]thymidine incorporation in response to ␣ 1D -AR activation may occur through JNK and/or other signaling cascades in this cell line.
As illustrated in Fig. 10 , we propose that agonist activation jpet.aspetjournals.org of the ␣ 1B -AR induces p38 kinase and ERK1/2 activation and increases protein biosynthesis. In addition, our results indicate that the ␣ 1B -AR uses both ERK1/2 and p38 kinasedependent pathways to induce protein biosynthesis. Use of two parallel pathways may explain the robust effect of agonist on protein synthesis in the ␣ 1B -AR relative to the ␣ 1D -AR cell line (Fig. 2) . In contrast to the regulatory properties of ␣ 1B -ARs, increases in protein biosynthesis occur primarily through constitutive ERK1/2 activity for the ␣ 1D -AR. Furthermore, inhibition of DNA replication occurs through an ERK1/2-independent pathway in both cell lines, suggesting that the profile of MAPK activity (i.e., ERK1/2 versus JNK or p38 kinase) may differentiate growth-related responses in Rat 1 fibroblasts.
